Direct-acting antiviral (DAA) therapy is safe highly effective in curing hepatitis C virus (HCV) in people who inject drugs (PWID) and no regimen is significantly more effective than the other. This according to a retrospective analysis performed on all HCV-infected patients treated at the Vancouver Infections Diseases Center between March 2014 and December 2017. All participants were enrolled in the multidisciplinary model of care. The primary outcome was achievement of SVR-12. Researchers found:
- 291 individuals (mean age 54 years, 88% PWID, 20% HCV treatment experienced) were enrolled and received interferon-free DAA HCV therapy.
- 207 individuals achieved SVR (90%), with 13 losses to follow-up, 7 relapses, and 2 premature treatment discontinuations.
- Intent-to-treat SVR analysis show the active PWID and treatment naïve patients were less likely to achieve SVR.
- Modified ITT analysis of active PWID showed no difference in achieving SVR compared to non-PWID.
Alimohammadi A, Holeksa J, Thiam A, Truong D, Conway B. Real-world efficacy of direct-acting antiviral therapy for HCV infection affecting people who inject drugs (PWID) delivered in a multidisciplinary setting. [Published online ahead of print May 23, 2018]. Open Forum Infect Dis. doi:10.1093/ofid/ofy120.
This Week's Must Reads
Must Reads in Hepatitis
Glecaprevir/Pibrentasvir Efficacy & Safety Assessed, J Hepatol; ePub 2018 Nov 23; D’Ambrosio, et al
HCV Infection Among Children & Young Persons, J Hepatol; ePub 2018 Nov 26; Modin, et al
HCV Patients with Limited Access to Antiviral Therapy, Dig Liver Dis; ePub 2018 Nov 29; Lens, et al
Progression in the Elimination of HCV Infection, PLoS One; ePub 2018 Dec 4; Juanbeltz, et al
Increased HCV Screening in Veteran Populations, Jt Comm J Qual Patient Saf; ePub 2018 Sep 25; Wray, et al